Cirrhosis

Casler, Kelly; Chaney, Amanda

doi:10.1097/01.npr.0000681772.39310.d0

Cited by 2 publications

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Association of PNPLA3 I148M with Liver Disease Biomarkers in Latinos

et al. 2021

View full text Add to dashboard Cite

Introduction. Liver disease accounts for approximately 2 million deaths per year worldwide. The majority of liver diseases are due to complications of cirrhosis, viral hepatitis, and hepatocellular carcinoma. Increased levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) may indicate liver disease. Moreover, there are additional noninvasive liver fibrosis indices that help to estimate liver damage, including AST to ALT ratio, AST to platelet ratio index (APRI), fibrosis-4 (FIB-4) score, and nonalcoholic fatty liver disease (NAFLD) fibrosis score. The aims of the present study were to (1) perform an association analysis of the patatin-like phospholipase domain containing 3 (PNPLA3) I148M (rs738409) variant with ALT, AST, and various liver fibrosis indices, and (2) determine whether there are gender related-differences in these associations. Methods. We obtained demographic, anthropometric, and metabolic phenotypes from Latino adult participants (n = 503, 64% female, 36.4 ± 0.5 years) from the Arizona Insulin Resistance (AIR) registry. SNP genotyping of I148M was performed using the TaqMan allelic discrimination assay. We used linear regression for the association analyses of the genotypes with ALT, AST, and the various liver fibrosis indices. We included genotype, age, body mass index (BMI), and alcohol status in the linear regression model. Results. The variant I148M was in Hardy-Weinberg equilibrium, with genotype distribution: non-risk CC = 118, heterozygous CG = 246, and risk GG = 139. The G allele was significantly associated with increased ALT and AST levels (p = 7.8 x 10-7 and p = 9.7 x 10-6, respectively). Moreover, we showed that the G allele was significantly associated with higher APRI (p = 3.7 x 10-7) and FIB-4 score (p = 4.1 x 10-3). When we analyzed the data by gender, we observed similar significant trends for ALT, AST, and APRI (all, p < 0.01). In females, the G allele was significantly associated with increased FIB-4 score (p = 6.9 x 10-3), which was not observed in the males (p > 0.05). There was no association of the I148M variant with AST/ALT ratio nor NAFLD risk score, whether analyzed in all adults or by gender. Discussion/Conclusion. Our findings provide additional evidence of an association of PNPLA3 I148M with several liver disease biomarkers in male and female Latinos residing in the Southwest of the United States.

show abstract

Association of PNPLA3 I148M with Liver Disease Biomarkers in Latinos

et al. 2021

View full text Add to dashboard Cite

show abstract

Prevalence and risk factors of anxiety and depression in patients with liver cirrhosis during the COVID-19 pandemic

Zhu

Zhang

Xiong

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Patients with cirrhosis are prone to mental and psychological problems. However, data on mental and psychological problems in patients with cirrhosis during the coronavirus disease 2019 (COVID-19) pandemic are lacking. Therefore, we aimed to investigate the prevalence and risk factors of anxiety and depression in this population. Methods The Patient Health Questionnaire-9 Scale and Generalized Anxiety Disorder 7-item scale were used to collect mental health data in this cross-sectional study. Multivariate logistic regression analysis was performed to evaluate the relevant influencing factors of anxiety and depression. Results The prevalence rates of anxiety and depression in patients with cirrhosis were 21.3% and 29.9%, respectively. Anxiety risk was higher among patients with cirrhosis who had significant abdominal pain and treatment interruption; COVID-19 vaccination was associated with anxiety reduction as a protective factor. Depression risk was higher among patients with cirrhosis for > 10 years, significant abdominal pain within one week, and treatment interruption. Course of cirrhosis of 5–10 years and COVID-19 vaccination were associated with the reduction of depression as protective factors. Conclusion COVID-19 vaccination is a protective factor for both depression and anxiety. Our findings may help healthcare professionals to develop appropriate treatment strategies and timely psychological interventions.

show abstract

Cirrhosis

Cited by 2 publications

References 45 publications

Association of <b><i>PNPLA3</i></b> I148M with Liver Disease Biomarkers in Latinos

Association of <b><i>PNPLA3</i></b> I148M with Liver Disease Biomarkers in Latinos

Prevalence and risk factors of anxiety and depression in patients with liver cirrhosis during the COVID-19 pandemic

Contact Info

Product

Resources

About